Medtech titan Medtronic says that it's not involved with research on an orgasm-inducing neurostimulation system, despite reports to the contrary.
Medical device industry giant Medtronic (NYSE:MDT) told MassDevice.com today that despite reports of the company's participation in upcoming studies, Medtronic is not involved with research on an implantable neurostimulator designed for treatment of sexual dysfunction.
Here's a look at some of the top funding stories for medical device companies this week.
EarLens said it raised some $36 million in an equity round for the hearing aid technology it's developing that uses infrared rather than sound waves.
Ascension Health Ventures
, Benvenue Medical Inc.
, Cheetah Medical
, Fletcher Spaght Ventures
, MVM Life Science Partners
, NxThera Inc.
, Robert Bosch Venture Capital
, Springfield Investments
Medtech titan Medtronic plans this year to launch clinical trials of an implanted neurostimulator designed to spur orgasm, starting with women.
Medical device industry giant Medtronic (NYSE:MDT) has signed on to launch human studies of an device designed to produce orgasms with the push of a button.
The European Patent Office revokes an Edwards Lifesciences transcatheter aortic valve patent that has been the center of a long-running feud with Medtronic.
Medtronic's alliance with insurance giant Aetna brings the medtech titan closer to the clinic through initiatives to target Type II diabetes patients with insulin pump therapy programs.
Spinal devices maker Vexim appoints as its director of marketing Sandrine Carle, a veteran of spinal operations at medtech giant Medtronic.
French spinal devices maker Vexim (EPA:ALVXM) this month welcome Medtronic (NYSE:MDT) veteran Sandrine Carle as its director of marketing.
Here's a look at some of the top personnel stories for medical device companies this week.